ClinicalTrials.gg

Program

HRS-3738

A development code.

In Jiangsu HengRui Medicine's pipeline, CRBN-E3. Its studies are mostly in Lymphoma, Non-Hodgkin, led by Jiangsu HengRui Medicine.

Furthest: phase 1, since Apr 25, 20221 company-led study, 1 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine11 open or runningphase 1since Apr 25, 2022Apr 25, 2022Dec 30, 2026phase 1 · NCT05363800
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-3738, phase 1, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 25, 2022First study: phase 1 study in RecurrenceFirst studyNCT05363800 · 74 enrolled · China

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in RecurrenceNCT05363800

TargetBeta

“CRBN-E3”the company's pipeline, read by Claude · source

Other programs on CRBN

ProgramCompanyFurthest phaseStudies
LenalidomideruleBristol-Myers Squibbphase 4109
pomalidomideruleBristol-Myers Squibbphase 451
mezigdomideBristol-Myers Squibbphase 312
golcadomideBristol-Myers Squibbphase 311
Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506Bristol-Myers Squibbphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05363800Recurrence · China1Active, not recruitingDec 30, 202674

How it is read

Names in the registry

  • “HRS-3738”, 1 entry

Codes read as this program: HRS3738.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.